The elucidation of additional costimulatory drugs potentiating LAG-3 blockade, and the effect of combining LAG-3 blockade with immunomodulatory drugs in other hematological malignancies typically displaying LAG-3 dysregulation, such as multiple myeloma, warrants further investigations [48,49,50]. Here, LAG3 is linked to plasma cell myeloma.